CRISPR-Cas9 Gene Editing (Doudna and Charpentier, 2012)

In 2012, Jennifer Doudna and Emmanuelle Charpentier published a landmark paper showing that a bacterial immune system protein, Cas9, could be programmed with a guide RNA to cut any target sequence in a genome with extraordinary precision — effectively giving humanity a find-and-replace function for DNA. In 2023, the FDA approved Casgevy, the first CRISPR-based therapy, offering a functional cure for sickle cell disease. Clinical trials are underway for cancer, HIV, and inherited blindness. Doudna and Charpentier won the 2020 Nobel Prize in Chemistry. The technology was repurposed from a mechanism bacteria evolved 3.5 billion years ago, making it one of the greatest acts of biological inspiration in history.